News | Treatment Planning | October 18, 2019

Partnership will connect participating sites to a central database to streamline review of radiation therapy treatment plans

MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment

October 18, 2019 — The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.

The goal of the platform is to establish an efficient framework to connect participating sites to a central database, allowing MD Anderson physicians to host collaborative review sessions around treatment plans and to communicate plan changes back to physicians. As the platform matures, it has the potential to be deployed at all MD Anderson locations and across MD Anderson Cancer Network.

“Radiation oncology is a highly technical specialty that relies on the interoperability of a variety of hardware and software components,” said Albert Koong, M.D., Ph.D., professor and division head of radiation oncology at MD Anderson. “We believe the development of this unified platform with Varian will enable expansion of our radiation oncology quality standards to provide the best available care to more patients.”

Watch the VIDEO: Walk Around of a Varian Identify Image-guided Patient Positioning System

MD Anderson Cancer Network, a program of MD Anderson Cancer Center, collaborates with community hospitals and healthcare systems around the globe to provide higher quality and advanced care to patients in the communities in which they live.

In addition to the software platform, the partnership will work to develop evidence-based tools to improve the analysis of various quality measures, with a focus on:

  • Minimizing the volume of radiation dose distributed to nearby healthy organs, resulting in fewer side effects for patients;

  • Automating the comparison of treatment plans to MD Anderson and national quality criteria, enabling the development of new standard value and safety metrics; and

  • Decreasing the time needed to review radiation treatment plans, improving efficiency and expanding access.

For more information: www.varian.com, www.mdanderson.org


Related Content

News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
News | Lung Imaging

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...

Time November 07, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Prostate Cancer

Sept. 30, 2025 – EDAP TMS's non-invasive, nonsurgical treatment option, Focal One Robotic HIFU, was featured on national ...

Time September 30, 2025
arrow
Subscribe Now